UFT/Leucovorin: An ‘Excellent Alternative’ to 5-FU/Leucovorin in Colorectal Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 14 No 8
Volume 14
Issue 8

NEW YORK-The combinationof UFT (an oral fluoropyrimidineconsisting of tegafur plus uracil) andleucovorin “is tolerable and efficacious”and “an excellent alternative to

NEW YORK-The combinationof UFT (an oral fluoropyrimidineconsisting of tegafur plus uracil) andleucovorin "is tolerable and efficacious"and "an excellent alternative tofluorouracil/leucovorin, according tothe results of a phase II multicentertrial (abstract 3608). "Prolonged administrationof UFT/leucovorin has asimilar toxicity profile to infusional 5-FU," the investigators concluded. Theyalso noted that UFT/leucovorin "comparesfavorably with other oral fluoropyrimidines"and saw "no disadvantagein treating the very elderly" (olderthan age 75).The principal toxicities were diarrheaand neutropenia. Grade 3/4 diarrheaoccurred in 23% of patients andgrade 3/4 neutropenia, in 5%. Othertoxicities included fatigue in 14.3%and nausea (but no grade 4 events) in10.7%. No cases of hand-foot syndromewere observed.Treatment Every 8 HoursA total of 58 patients were enrolledin the Eastern Cooperative OncologyGroup (ECOG) study 1299. The medianage of patients was 81 years (range75-90 years). Performance status was0 for 14 patients (24%), 1 for 31 patients(56%), and 2 for 13 patients(20%). Patients had undergone noprior chemotherapy for metastaticdisease, but 13 patients had undergoneprior adjuvant chemotherapy.

Treatment was administered asUFT (300 mg/m2) plus leucovorin (30mg) every 8 hours for 28 days, with 7days of rest. CT scans were performedevery 2 weeks.Similar Results toSingle-Agent 5-FUAccording to updated data presentedby Elizabeta C. Popa, MD, of NewYork University Cancer Institute, thebest confirmed responses among the55 treated patients were a completeresponse in 1 patient and a partialresponse in 11 patients. Eighteen patientshad stable disease and 16 hadprogressive disease. Nine patients werenot evaluable (Table 1).Results are similar to the 22% responserate and 13-month median survivalreported for single-agent 5-FU."Phase III studies comparing bolus IV5-FU and oral UFT/leucovorin haveshown similar response rates and survivaloutcomes to our study," Dr. Popaadded.The investigators said that additionalstudies comparing infusional 5-FU with oral UFT/leucovorin, as wellas phase II studies using UFT/leucovorinin combination with newer agents,such as oxaliplatin (Eloxatin), irinotecan(Camptosar), and biologics, "arewarranted to establish maximal utilityof this oral fluoropyrimidine."

Related Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
Related Content